This enduring recording from the 2024 ASCP annual meeting is designed to review recent data, clinical cases, and practical considerations when performing and interpreting HER2 testing across different types of tumors. Faculty will also provide practical tips to prepare pathologists and laboratory professionals for a new era of pan-tumor HER2 testing. Based on recent clinical data and new treatment options for patients, laboratories need to be equipped to perform HER2 testing across multiple types of unresectable or metastatic solid tumors.
Provided by the American Society for Clinical Pathology in partnership with Q Synthesis LLC.
Course topics include:
- Review of recent clinical data and new treatment options related to HER2 testing
- HER2 testing in patients with advanced solid tumors
- HER2-directed therapy and clinical outcomes
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Learning Objectives
- Identify when HER2 testing may be indicated in patients with advanced solid tumors
- Describe how the use of certain HER2-directed therapy may impact clinical outcomes in patients with different types of solid tumors
- Outline how HER2 testing may be performed in different types of solid tumors
- Design laboratory workflows to achieve efficient, accurate, and equitable pan-tumor HER2 testing
Faculty
Joseph Kim, MD, MPH, MBA
President, Q Synthesis LLC
Jefree Schulte, MD
Assistant Professor, Department of Pathology and Laboratory Medicine
University of Wisconsin, Madison, WI
Wei Zhang, MD, Ph.D.
Associate Professor, Pathology and Laboratory Medicine
University of Kansas, Kansas City, KS
Faculty Disclosures
Dr. Joseph Kim and Dr. Jefree Schulte have no financial relationships to disclose. All financial relationships for Dr. Wei Zhang have been mitigated.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of 1.0 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.:
Method of Participation
To complete the activity and receive credit, the participant must attend the program. CME certificates will be provided on-line.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.